drugset
drugset / Trial / NCT04286607

Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

NCT04286607 ↗

Phase 3 Completed 333 enrolled Arcutis Biotherapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 24 weeks by subjects with chronic plaque psoriasis

Timeline

Start
2020-02-12
Primary completion
2024-01-22
Completion
2024-01-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Roflumilast Small molecule 0.3 % Topical

Indications

psoriasis